Comera Life Sciences announces expansion of patent portfolio

Comera Life Sciences announced the expansion of its patent portfolio with one new patent granted in South Korea and two Notices of Allowance in the U.S. and Japan covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore platform. The recent developments consist of the following: Notice of Allowance from the United States Patent and Trademark Office for expansion of core viscosity reduction patent claims toward antibody formulations and processing improvements with new excipient 1,3-dimethyluracil. Issuance of South Korean Patent No. 2493469, which provides Comera exclusive rights pertaining to excipients hordenine, tryptamine, and trigonelline, with or without caffeine, in its SQore(TM) platform as viscosity-lowering agents. Notice of Allowance from Japan’s Patent Office for Japanese Patent Application No. 2020-546123, titled "Excipient compounds for protein formulations," for hordenine as viscosity-reducing excipient. "This patent and two Notices of Allowance strengthen Comera’s robust, global patent portfolio with both expansion of claims to our core SQore platform and also geographic expansion outside of the U.S.," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. "In conjunction with our existing patents, we believe this expanded intellectual property portfolio will provide value for our existing and future partners by increasing the potential commercial market and lifecycle extension opportunities with our SQore platform."